Clinical Trials Logo

Chemotherapy clinical trials

View clinical trials related to Chemotherapy.

Filter by:

NCT ID: NCT01307878 Completed - Clinical trials for Colorectal Neoplasms

New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases

Start date: June 2012
Phase: Phase 3
Study type: Interventional

To evaluate the survival benefit of pre-operation chemotherapy of primary tumor tesection (PTR) compared upfront PTR for colorectal cancer (CRC) patients with an asymptomatic resectable primary tumor and synchronous unresectable liver-limited metastases with conversion therapy intent.

NCT ID: NCT01303978 Completed - Clinical trials for Chemotherapy-induced Nausea and Vomiting

Phase II Proof-of-concept Study of APD421

Start date: February 2011
Phase: Phase 2
Study type: Interventional

Evaluation of efficacy of APD421 in preventing nausea and vomiting caused by cisplatin

NCT ID: NCT01132014 Completed - Ovarian Cancer Clinical Trials

Autologous OC-DC Vaccine in Ovarian Cancer

Start date: May 2010
Phase: Early Phase 1
Study type: Interventional

This is a Five cohort sequential clinical trial for subjects with recurrent ovarian, fallopian tube, or primary peritoneal cancer to determine the feasibility and safety as well as immunogenicity of OC-DC, an autologous vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous oxidized tumor cells, administered intranodally alone, or in combination with intravenous Bevacizumab and cyclophosphamide or in combination with intravenous Bevacizumab, cyclophosphamide and aspirin. Study duration is 24 months.

NCT ID: NCT01111851 Completed - Clinical trials for Chemotherapy-Induced Nausea and Vomiting (CINV)

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

Start date: April 2010
Phase: Phase 1
Study type: Interventional

This study will evaluate if the mean value of brain neurokinin 1 (NK1)-receptor occupancy of participants treated with aprepitant is similar to that of participants treated with fosaprepitant at certain timepoints.

NCT ID: NCT01074255 Completed - Clinical trials for Chemotherapy-induced Nausea and Vomiting

Re-examination Study of EMEND (Aprepitant) (MK-0869-184)

Start date: April 2007
Phase: N/A
Study type: Observational

This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation. Its aim is to reconfirm the clinical usefulness of EMEMD (aprepitant) through collecting the safety information according to the Re-examination Regulation for New Drugs.

NCT ID: NCT01037933 Completed - Cancer Clinical Trials

Comedy in Chemotherapy (COMIC) Study

COMIC
Start date: February 2007
Phase: Phase 2
Study type: Interventional

Primary aims: To compare changes in (a) symptoms related to cancer and chemotherapy, (b) a marker of immune function (salivary immunoglobulin A), and (c) a hormonal marker of emotional stress (salivary cortisol) between two groups of patients who view a humorous or non-humorous DVD. Secondary aim: To describe the perception of patients, caregivers, and nurses regarding the overall intervention experience.

NCT ID: NCT01031498 Completed - Clinical trials for Acute Myelogenous Leukemia

Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting

Start date: September 2005
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to compare the effectiveness of 3 drug schedules in preventing chemotherapy-related nausea and/or vomiting in patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS).

NCT ID: NCT01023802 Completed - Breast Cancer Clinical Trials

The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer

Start date: February 2009
Phase: N/A
Study type: Observational

In patients with breast cancer who undergo neoadjuvant chemotherapy or neoadjuvant hormone therapy molecular breast imaging (MBI) is an accurate test for assessing response rate to neoadjuvant therapy.

NCT ID: NCT01018758 Completed - Clinical trials for Chemotherapy-Induced Nausea and Vomiting

Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy

NHLPal
Start date: July 2006
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter phase II study in patients with aggressive Non Hodgkin Lymphoma scheduled to receive moderately emetogenic polychemotherapy (according to modified Hesketh classification for antiemetic therapy).

NCT ID: NCT01012336 Completed - Ovarian Cancer Clinical Trials

Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin

Start date: May 2010
Phase: Phase 2
Study type: Interventional

The current recommended guideline for patients receiving moderately emetogenic chemotherapy (MEC) is the combination of a 5-HT3 receptor antagonist and corticosteroid. Incidence of chemotherapy induced nausea and vomiting (CINV) is approximately 50% in patients receiving MEC. An incidence rate of 25-38% for delayed emesis and 55-60% for delayed nausea has been observed. Hence, there is clearly a need for more effective prevention of CINV in patients receiving MEC, especially in women with ovarian carcinoma who are particularly susceptible to these symptoms. Therefore the investigators designed a study with the objective to evaluate if new combination (Aprepitant/Ramosetron/Dexamethasone) may improve actual CINV control in ovarian carcinoma patients treated with taxane/carboplatin.